TNFRSF8 and non-Hodgkin lymphoma: For example, CD20 and CD30 are common biomarkers for lymphoma imaging [180,181,182] and the Food and Drug Administration approved a CD20-specific chimeric mAb, Rituximab, for the treatment of non-Hodgkin’s lymphoma (NHL) and rheumatoid arthritis (RA).